financetom
Business
financetom
/
Business
/
Celanese's Elevated Debt, Earnings Risks Increase Financial Uncertainty, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Celanese's Elevated Debt, Earnings Risks Increase Financial Uncertainty, UBS Says
Nov 11, 2024 10:21 AM

12:45 PM EST, 11/11/2024 (MT Newswires) -- Celanese's (CE) recent results and weaker market outlook have created more concerns about the company's ability to manage its debt load, UBS Securities said in a note on Monday.

Celanese's multiple "will stay compressed for the foreseeable future, and we can't rule out further stock downside if market concerns increase," UBS said.

UBS said that the anticipated synergies with DuPont's ( DD ) nylon-engineered plastics business have been offset by decreased profit margins due to the changing product mix, cultural integration issues, or rising competition from China and Asia.

With global acetic acid capacity forecast to grow and potential declines in global energy prices, cost pressures for Celanese could increase, according to the note. The company could need about $2 billion in additional funding by 2026 to 2028 if the situation does note improve.

UBS downgraded its rating on Celanese to neutral from buy and reduced the price target to $97 from $161.

Shares of the company were down 4% in recent trading.

Price: 81.36, Change: -3.44, Percent Change: -4.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases
Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases
Oct 7, 2025
08:34 AM EDT, 10/07/2025 (MT Newswires) -- Jade Biosciences ( JBIO ) on Tuesday unveiled its JADE201 monoclonal antibody, which it said has the potential to treat a broad range of autoimmune diseases. Jade said it plans to begin a randomized, placebo-controlled study evaluating JADE201 in patients with rheumatoid arthritis in H1 2026. JADE201 is an investigational half-life extended, afucosylated...
Ivanhoe Mines hits record zinc output in Congo's Kipushi mine
Ivanhoe Mines hits record zinc output in Congo's Kipushi mine
Oct 7, 2025
DAKAR, Oct 7 (Reuters) - Ivanhoe Mines ( IVPAF ) produced 71,226 metric tons of copper and a record 57,200 tons of zinc in the third quarter from its flagship Kamoa-Kakula and Kipushi mines in the Democratic Republic of Congo, the company said on Tuesday. The Vancouver-based miner said robust copper output kept it on track to meet full-year production...
Envoy Medical Shares Soar 140% Pre-Bell Following FDA Approval of Expanded Acclaim Cochlear Implant Trial
Envoy Medical Shares Soar 140% Pre-Bell Following FDA Approval of Expanded Acclaim Cochlear Implant Trial
Oct 7, 2025
08:36 AM EDT, 10/07/2025 (MT Newswires) -- Envoy Medical ( COCH ) shares soared 140% in Tuesday's premarket session after the company said it was granted US Food and Drug Administration approval to expand a clinical trial of its fully implanted Acclaim cochlear implant to the final stage. The company said the approval, which was based on three-month data from...
GXO Renews Dolce&Gabbana Beauty Logistics Deal, Adds Italian Warehouse
GXO Renews Dolce&Gabbana Beauty Logistics Deal, Adds Italian Warehouse
Oct 7, 2025
08:35 AM EDT, 10/07/2025 (MT Newswires) -- GXO Logistics ( GXO ) said Tuesday that it has renewed a long-term agreement with Dolce&Gabbana Beauty to operate a new dedicated site in Calvenzano, Italy, and handle orders for global distribution, returns, and other services. The roughly 25,000-square-meter facility will manage inbound, stocking, outbound, and value-added work for beauty products, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved